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The central nervous system (CNS) is a highly complex network comprising long-lived
neurons and glial cells. Accordingly, numerousmechanisms have evolved to tightly regulate
the initiation of inﬂammatory responses within the brain. Under neuroinﬂammatory
conditions, as in the case of viral encephalitides, the inﬁltration of leukocytes is often
required for efﬁcient viral clearance and recovery.The orchestration of leukocyte migration
into the inﬂamed CNS is largely coordinated by a large family of chemotactic cytokines
and their receptors. In this review, we will summarize our current understanding of how
chemokines promote protection or pathogenesis during arbovirus induced encephalitis,
focusing on neurotropic ﬂaviviruses and alphaviruses. Furthermore, we will highlight the
latest developments in chemokine and chemokine receptor based drugs that could have
potential as therapeutics and have been shown to play a pivotal role in shaping the outcome
of disease.
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INTRODUCTION
Arboviruses (arthropod-borne viruses) are a signiﬁcant cause of
human morbidity and mortality and have worldwide distribution.
In recent years, these viruses have become an increasing public
health concern due to climate change, increased globalization, and
other environmental factors, that have caused their unexpected
geographic expansion and increased the frequency of outbreaks
(Gubler, 1996). TheWorldHealthOrganization has estimated that
arboviral infections constitute ∼30% of all emerging infectious
diseases in the past decade (Jones et al., 2008). Themost recent and
well-documented examples include the introduction and spread
of WNV in North America in 1999 and the continuing emergence
of CHIKV in the regions of the Indian Ocean in 2005/2006 (Hayes
et al., 2005; Bonn, 2006).
Neurotropic arboviruses have the capacity to enter theCNS and
cause inﬂammation and severe neurologic sequelae in humans.
Many of these viruses are members of the Flavivirus (Flaviviri-
dae family) and Alphavirus (Togaviridae family) genera. The
main perpetrators of arboviral infections in humans include
JEV, with 30,000–50,000 cases reported annually, WNV, and
TBEV (Campbell et al., 2011). Mosquito-borne alphaviruses are
also important causes of encephalomyelitis and include WEEV,
EEEV, and VEEV. SFV and SINV are neurotropic viruses that
Abbreviations: BBB, blood–brain barrier; BCSFB, blood–cerebrospinal ﬂuid bar-
rier; CHIKV, Chikungunya virus; CNS, central nervous system; CSF, cerebrospinal
ﬂuid; DC, dendritic cell; EEEV, Eastern equine encephalitis virus; FDA, Food
and drug administration; HIV, human immunodeﬁciency virus; iNOS, inducible
nitric oxide synthetase; JEV, Japanese encephalitis virus; MHC, major histocompat-
ibility complex; MVEV, Murray valley encephalitis virus; SCID, severe combined
immunodeﬁciency; SFV, Semliki Forest virus; SINV, Sindbis virus; TBEV, tick borne
encephalitis virus; TLR, toll-like receptor; TNF-α, tumor necrosis factor alpha;
VEEV, Venezuelan equine encephalitis virus; WEEV, Western equine encephalitis
virus; WNV, West Nile virus.
do not usually cause encephalitis in humans, but are stud-
ied frequently in mice as model systems for alphavirus-induced
encephalomyelitis.
Acute viral encephalitis is a life-threatening condition that
is characterized by the presence of leukocytes within the brain
parenchyma.Viral replicationwithin theCNS can lead to neuronal
damage and results in apoptosis and necrosis of these cells. As part
of innate and adaptive immune responses to viral replication, a
large number of leukocytes inﬁltrate the CNS, and the cell types
and composition of the inﬂammatory response can vary greatly
between individuals and between pathogens. The large inﬂux of
leukocytes into the normally immune-sheltered CNS is required
for recovery and clearance of virus but is often associatedwith neu-
ropathology (Hosking and Lane, 2010; Ransohoff and Engelhardt,
2012).
Chemokines play a pivotal role in the attraction of leukocytes
into theCNS,and it is imperative to understand their cell-type spe-
ciﬁc role in pathogenesis in order to develop novel immunothera-
peutics and predict the impact of chemokine receptor antagonism
in humans. Chemokines and their receptors comprise a large
superfamily of proteins that can be categorized into four subfam-
ilies based on the position of the ﬁrst two cysteines within the ﬁrst
amino terminal cysteine motif: CC, CXC, XC, and CX3C (Zlotnik
and Yoshie, 2000). All chemokine receptors are G-protein coupled
receptors, containing a seven-transmembrane domain that inter-
acts with the appropriate chemokine upon binding. Chemokines
and chemokine receptors have been shown to have pivotal roles in
organizing and coordinating complex immune system functions
(Zlotnik and Yoshie, 2012). Many studies have been conducted in
the past to elucidate the role of chemokines during viral encephali-
tis. In this review, we will summarize the role of chemokines and
their receptors speciﬁcally during arbovirus induced encephalitis.
In particular, we will focus on WNV, JEV, TBEV, SFV, and SINV, as
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these pathogens are the most studied in the context of chemokine-
mediated leukocyte inﬁltration into the virally infected CNS in
both mouse models and humans. Furthermore, we will also high-
light chemokine receptor based drugs that are either approved
or in development for human use, as well as chemokine speciﬁc
antibodies, and their anticipated effect in the context of human
arboviral encephalitis.
IMMUNE RESPONSES IN THE CNS DURING ARBOVIRAL
ENCEPHALITIS
From an immunological point of view, the CNS is a unique com-
partment due to the following features: lack of antigen presenting
cells, low expression of MHC I and MHC-II, lack of lymphatic
vessels within the brain, absence of resident DC, BBB, and BCSFB
that restrict entry of cells and substances into the CNS (Ransohoff
et al., 2003). If the BBB is compromised due to infection or inﬂam-
mation, immune cells are able to inﬁltrate the brain (Rivest, 2009).
Despite the mostly effective host responses during early stages of
viral infection, controlling viral spread within the CNS requires
the inﬂux of peripheral leukocytes that can often cause profound
damage to neurons and glial cells. Therefore, immune responses
within the host must be balanced as to prevent damage to delicate
and mostly non-renewable neurons.
Neurotropic arboviruses replicate in the periphery prior to
entry and replication in the tissue of the CNS. Within periph-
eral organs or lymphoid tissues, the elicited immune response
is often sufﬁcient to prevent viral entry into the CNS. In fact,
most infections with ﬂaviviruses are asymptomatic/subclinical,
with no evidence of neuroinvasion (Mostashari et al., 2001). How-
ever, if the virus enters the CNS, the infected target cells as well
as bystander cells produce numerous chemokines and cytokines,
which in turn initiate neuroinﬂammation (Neumann, 2001).
Based on several RNA based assays, some of the chemokines pro-
duced within the CNS during arboviral encephalitis are CCL1–5,
CCL7,CCL8,CCL12, CXCL1,CXCL2, andCXCL9–13 (Gupta and
Rao, 2011; Yang et al., 2011; Metcalf et al., 2013; Palus et al., 2013;
Michlmayr et al., 2014). In particular CCL2–CCL5 and CXCL10
are consistently and highly induced during JEV,WNV, TBEV, SFV,
and SINV infection. In addition to infected neurons, activated
astrocytes and microglia are also a major source of chemokines
within the inﬂamed brain. Our study and a study by Shirato et al.
has revealed that the extent of chemokine expression duringWNV
infection is dependent on viral strain and severity of the disease
(Shirato et al., 2004; Michlmayr et al., 2014). Another study with
TBEV has shown that mice highly susceptible to TBEV infection
display a higher fold induction of chemokine transcripts and low
levels of neutralizing antibodies compared to mice with low sus-
ceptibility to TBEV infection. Thus, the extent of the host response
may be positively correlated with pathogenesis of TBEV infection
in mice (Palus et al., 2013).
The leukocytic inﬁltrate and its role within the CNS during
viral encephalitis is dependent on numerous factors, including
the infected cell type, the route of infection, and the strain and
inoculum of virus. Evaluation of human and mouse CNS tissue
indicates that neutrophils, CD4+ and CD8+ T-cells, and mono-
cytes/macrophages are typically present during viral infection
(Parsons and Webb, 1982; Johnson et al., 1986; Williamson et al.,
1991; Holub et al., 2002; Samuel and Diamond, 2006). Currently,
the role of neutrophils during neurotropic viral infections, both in
the periphery and within the CNS, is unclear. Antibody depletion
of neutrophils results in variable outcomes, depending on the virus
used and timing of administration; the receptors used to enter the
CNS have not been studied. T-cells, in particular CD8+ T-cells,
are a critical component of the cellular inﬁltrate into the brain
(Shrestha et al., 2005; Sitati and Diamond, 2006), and blockade of
T-cell entry into virally infected brains often results in changes in
CNS viral loads and survival in mice. Whether T-cells are protec-
tive or pathogenic during viral encephalitis depends on the virus.
Whereas T-cells play a predominantly protective role duringWNV
infection by mediating viral clearance in a perforin and granzyme-
dependent manner (Shrestha et al., 2005; Sitati and Diamond,
2006), T-cells play a pathogenic role during TBEV infection, since
CD8−/− mice and SCID mice showed increased survival (Ru˚žek
et al., 2009). For monocytes/macrophages, it is clear that these
cells do function in regulating pathogenesis, but this appears to be
highly dependent on the strain of virus used, as well as the model
of infection. Thus, it appears that the biological roles of speciﬁc
cell subsets and the complex signals involved in their migration
and function are highly dependent on the context of infection,
as well as the virus itself. In this review, we will summarize the
current understanding of the chemokine receptors CCR2, CCR5,
CXCR2, CXCR3, and CXCR4 during ﬂavivirus and alphavirus
infection, focusing on the effect of therapeutic blockade of these
receptors using small molecule receptor antagonists or chemokine
neutralizing antibodies.
THE ROLE OF CHEMOKINE RECEPTORS IN THE
PATHOGENESIS OF ARBOVIRAL ENCEPHALITIS
CCR2
CCR2 is often considered to be a receptor associated with mono-
cyte trafﬁcking, which is consistent with its high and uniform
expression on Ly6chi “inﬂammatory” monocytes (Mack et al.,
2001; Geissmann et al., 2003). This receptor is also found on
subsets of activated T-cells, DC, and NK cells. In humans, a func-
tionally equivalent “inﬂammatory” monocyte subset, identiﬁed
as CD14+CD16− also uniformly expresses CCR2 (Auffray et al.,
2009). The primary and speciﬁc ligand for CCR2 is CCL2, but this
receptor can also bind to ligands CCL7 and CCL12/CCL13 (Zlot-
nik and Yoshie, 2000). CCR2 has been postulated to be critical for
the migration of monocytes into tissues during various inﬂam-
matory conditions (Figure 1). Recently, a novel role for CCR2 in
regulating monocyte egress from the bone marrow under home-
ostatic and inﬂammatory conditions has been identiﬁed (Serbina
and Pamer, 2006; Tsou et al., 2007). Thus genetic deﬁciency of
CCR2 results in severe monocytopenia that could account for the
partial or entire loss of these cells in inﬂamed tissues. The mech-
anism by which CCR2 modulates monocyte egress from the bone
marrow into blood involves stromal cell sensing of TLR ligands,
including those involved in viral sensing within the bone marrow.
This results in the production of CCL2 within hours after infec-
tion, thus providing a mechanism by which systemic infections
can trigger monocyte release (Shi et al., 2011). Thus, CCR2 and
its ligands CCL2 and CCL7 are critical for modulating circulat-
ing monocyte numbers, and the additional role of this receptor in
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FIGURE 1 |The dual role of CCR2-expressing monocytes duringWest
Nile virus (WNV) infection.The function of CCR2 on monocytes may
involve two distinct steps: egress from the bone marrow induced early
followingWNV infection, and their migration into theWNV-infected central
nervous system (CNS). However, the role of CCR2-expressing monocytes
is highly dependent on the mode of infection utilized in mouse models.
With peripheral infection (A), WNV induces a monocytosis within several
days post infection. Genetic deﬁciency or pharmacological blockade of
CCR2 in mice (red arrow) results in monocytopenia and leads to decreased
monocyte inﬁltration into the CNS, enhanced viral titers in the brain and
increased mortality. Therefore, CCR2-mediated monocytosis and the
subsequent migration of monocytes into the inﬂamed CNS are protective
(green arrows). In contrast using an intranasal infection model ofWNV
infection (B), the migration of CCR2-expressing monocytes into the CNS
has also been shown to promote pathogenesis (red arrow) in mice. Thus,
blocking CCR2 using anti-CCL2 antibodies in this model prolongs survival
(green) in mice.
mediating migration from the blood into inﬂamed organs like the
CNS, may be context-dependent (Shi et al., 2011).
Monocytes appear to have a critical role during WNV infec-
tion, although whether these cells function to protect or promote
pathogenesis is unclear. Several studies have evaluated the role of
monocytes using clodronate-loaded liposomes. In the ﬁrst study,
mice were infected intraperitoneally using a non-neuroinvasive
strain of WNV, and monocyte depletion resulted in increased
viremia, enhanced viral entry into the CNS, and increased mortal-
ity (Ben-Nathan et al., 1996). Another study, using subcutaneous
inoculation of a neurotropic strain of WNV, showed a signiﬁcant
increase in peripheral and CNS viral loads and increased mortality
following clodronate treatment (Purtha et al., 2008). Both stud-
ies imply that monocytes play a protective role in the context of
WNV encephalitis (Figure 1). In a third study that utilized a lethal
intranasal model and a non-neurotropic strain of WNV, depletion
of peripheral monocytes, after treatment with clodronate, resulted
in a reduction of CD11b+ cells in the WNV-infected brain during
WNV encephalitis (Getts et al., 2008). The authors blocked Ly6chi
monocyte migration into the CNS using an anti-CCL2 antibody
and found a prolonged survival time compared to isotype-treated
mice (Table 1), suggesting that inﬂammatory monocytes may
function pathogenically during WNV encephalitis in this model
(Figure 1).
Using Ccr2-deﬁcient mice, which are monocytopenic, we
observed higher mortality and enhanced viral titers in the CNS
during WNV infection compared to wild type mice, supporting
a protective role of CCR2 (Lim et al., 2011). Detailed analysis of
monocytosis revealed that WNV induces an approximate ﬁvefold
increase in Ly6chi monocytes in the blood within the ﬁrst 5 days
post infection. This response was found to be entirely dependent
on CCR2, since Ccr2−/− mice showed no increase in monocyte
levels in the blood throughout the course of infection. Within
the CNS, a speciﬁc loss of Ly6chi monocytes was observed, while
other inﬁltrating leukocyte subsets (CD4+ andCD8+ T-cells, neu-
trophils, and NK cells) remained unchanged compared to wild
type controls, correlating the speciﬁc loss of inﬂammatory mono-
cyte accumulation in the CNS with increased mortality. Adoptive
transfer of monocytes into WNV-infected Ccr2−/− mice showed
that both CCR2-expressing and CCR2-deﬁcient monocytes were
capable of entering the CNS, suggesting monocyte migration into
the CNS is CCR2-independent.
Because of the signiﬁcant role of CCR2 in monocytosis during
WNV infection, the induction of its ligands, CCL2, CCL7, and
CCL12/CCL13 is implicit. Indeed, CCL2 is detected in the plasma
of WNV-infected blood donors during the acute phase of infec-
tion, and numerous studies have also shown strong induction of
CCL2 in vitro (Tobler et al., 2008; Semple et al., 2010; Hussmann
et al., 2013). Among the CCR2 ligands, it appears that CCL2 and
CCL7play adominant role in regulatingCCR2-mediatedmonocy-
tosis, while CCL12 was dispensable at the steady state (Tsou et al.,
2007). It is unclear at the moment which of these chemokines
(or both) is involved in WNV-induced monocytosis, and whether
migration from the blood into the CNS requires either or both of
these ligands.
Very little is known regarding the role of monocytes or CCR2
during other ﬂavivirus or alphavirus infections. In the context of
JEV and TBEV infection, CCL2 has been detected in the plasma
and CSF of patients (Michałowska-Wender et al., 2006; Gupta
et al., 2010); however, no studies have evaluated the role of mono-
cytes or CCR2 in the context of these infections in mice. For
alphavirus infections, we recently showed that the CCR2 ligand,
CCL2, is highly inducible in the brain during SFV infection in
mice (Michlmayr et al., 2014). The extent of CCL2 upregulation
was correlated with the virulence of the strain, with the viru-
lent strain of SFV inducing a >3000-fold induction above healthy
control brains versus an ∼90-fold induction using the avirulent
strain of SFV. Interestingly, the composition of the CNS inﬁl-
trate differed greatly between these two strains, with the avirulent
strain inducing Ly6Chi monocyte inﬁltration followed by a large
inﬂux of T-cells at the peak of infection. Conversely, the viru-
lent strain of SFV induced an early and large inﬂux of monocytes,
with mice succumbing to infection by day 6, prior to when T-
cells typically appear in the CNS. To investigate the role of CCR2
in this model, we infected Ccr2-deﬁcient mice with virulent SFV
but found no signiﬁcant change in survival (data not shown).
We also evaluated the therapeutic potential of CCR2 blockade
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Table 1 | Inhibitors of chemokines/receptors and their role in arboviral encephalitis pathogenesis.
Blockade Compound or antibody Pathogen model Role of antagonist Reference
Receptor antagonists
CCR2 RS504393 SFV No effect Michlmayr et al. (2014)
CCR5 DAPTA SFV No effect Michlmayr et al. (2014)
CXCR3 Compound 21 SFV No effect Michlmayr et al. (2014)
CXCR3 & CCR2 Compound 21 and RS504393 SFV Beneﬁcial Michlmayr et al. (2014)
CXCR4 AMD3100 WNV Beneﬁcial McCandless et al. (2008)
Antibodies
CXCL10 1F11 or 1B9 WNV Pathogenic Klein et al. (2005)
CCL2 2H5 WNV Beneﬁcial Getts et al. (2008)
The role of chemokine/receptor blockade can be either beneﬁcial, pathogenic or have no effect on disease outcome in murine models of encephalitis.
during SFV infection using a CCR2-speciﬁc antagonist, RS504393,
which is a highly selective small molecule inhibitor (Mirzade-
gan et al., 2000; Furuichi et al., 2003). Treatment of SFV-infected
mice twice per day, starting on day 3, resulted in no signiﬁcant
change in survival compared to untreated mice (Michlmayr et al.,
2014). In both Ccr2−/− mice and RS504393-treated mice, dras-
tically reduced monocyte numbers were observed in the CNS
compared to control-infected mice. Interestingly, brain viral titers
in Ccr2−/− and RS504393-treated versus control mice were not
signiﬁcantly altered (Table 1), suggesting that monocytes may
not contribute to viral clearance in the CNS (Michlmayr et al.,
2014). Together, these results suggest that monocytes, although
they migrate into the CNS during SFV infection of mice, may
not impact pathogenesis. More work is required to fully under-
stand monocyte migration and function during SFV and other
alphavirus infections.
CCR2 receptor antagonists
There is great interest in developing a CCR2-speciﬁc antagonist
due to pathogenic roles of monocytes in a wide range of inﬂam-
matory diseases (Bachelerie et al., 2013). Currently, several small
molecule receptor antagonists have made it successfully into clin-
ical trials, including JNJ-17166864 developed by Johnson and
Johnson, CCX140 from ChemoCentryx, and a CCR2-neutralizing
antibody from Millenium (Hou et al., 2008; Hanefeld et al., 2012;
Bachelerie et al., 2013). Based on our current understanding of
how monocytes function during viral infection of the CNS, it
would be expected that blocking monocyte entry into the CNS
via CCR2 blockade, either by preventing their egress from the
bone marrow or their migration into the CNS, could be detrimen-
tal to the patient during natural infection. However, our studies
using SFV infection as a model of neurotropic alphavirus infec-
tion suggest that CCR2 blockade in this context may have no effect
(Michlmayr et al., 2014).
CCR5
Due to its role as an HIV-1 co-receptor, CCR5 is one of the most
highly studied chemokine receptors to date (Deng et al., 1996;
Dragic et al., 1996). This receptor is mainly expressed on subsets of
activated T-cells, NK-cells and myeloid cells (Figure 2), including
monocytes, DCs, and microglia (Mack et al., 2001). Until recently,
the function of CCR5 in host defense in humans was thought to be
redundant with other closely related receptors, since individuals
genetically deﬁcient for CCR5 showed no increased susceptibil-
ity to infectious agents (Lim et al., 2006). However, recent studies
have provided evidence that CCR5 may have a neuroprotective
role during acute ﬂaviviral infections of the CNS in both mice and
humans.
The CCR5 ligands, CCL3, CCL4, and CCL5 have been shown
to be among the most highly upregulated chemokines in the CNS
during WNV, TBEV, JEV, and SFV infection in mice and humans
(Glass et al., 2005; Klein et al., 2005; Palus et al., 2013; Michlmayr
et al., 2014). The source of these ligands in vivo is unclear; how-
ever, in vitro studies, using primary cell cultures, suggest that, at
least for CCL5, the major source could be astrocytes and possi-
bly microglia (Cheeran et al., 2005; Chen et al., 2011; Hussmann
and Fredericksen, 2014). The extent of CCL5 production may be
dependent on the pathogenic potential of the virus, with astrocytes
producing signiﬁcantly higher levels of CCL5 when encounter-
ing a more virulent strain of WNV (Hussmann and Fredericksen,
2014). In WNV-infected plasma samples from blood donors dur-
ing the viremic phase of infection, none of the CCR5 ligands were
elevated above control levels (Tobler et al., 2008). However, in
the context of JEV infection, CCL5 levels detected in human CSF
appeared to be positively correlated with leukocyte numbers in
the CSF. Additionally, plasma levels of CCL5 were signiﬁcantly
elevated in fatal compared to non-fatal human cases (Winter et al.,
2004).
Pathogenesis studies in mice have revealed a critical role for
CCR5 during ﬂavivirus infection. In the context of WNV infec-
tion, signiﬁcant differences were observed only within the CNS,
with Ccr5−/− mice exhibiting increased viral loads, concomitant
with reduced accumulation of inﬁltrating CD4+ and CD8+ T-
cells, NK cells and monocytes/macrophages (Glass et al., 2005).
The loss of these cells correlated with 100% mortality in Ccr5−/−
mice compared to wild type controls, where survival was docu-
mented to be ∼35%. Of note, viral clearance from the spleen in
both Ccr5−/− and wild type mice was identical and underlines
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FIGURE 2 |The role of CCR5 during flavivirus-induced encephalitis.
During WNV and Japanese encephalitis virus (JEV) infection in mice, the
migration of CD4+ T-cells, CD8+ T-cells, NK-cells and monocytes from
the blood into CNS is required for efﬁcient control of viral replication
and recovery (upper). In the absence of CCR5 in mice, the migration of
these leukocytes into the CNS is delayed and/or severely impaired
(lower). During JEV infection, the absence of CCR5 also results in
inefﬁcient NK and CD8+ T-cell effector functions as well. Although the
function of CCR5 has not been evaluated during WNV infection in
humans, homozygosity for the complete loss-of-function mutation,
CCR532, has been correlated with increased severity of WNV and tick
borne encephalitis virus infections. It is anticipated that blockade of
CCR5, either in mice or humans, may increase susceptibility to
neurotropic ﬂaviviruses.
the importance of a CNS speciﬁc role of CCR5 in WNV-infected
mice. Adoptive transfer of CCR5+ splenocytes into Ccr5−/− mice
restored the survival rate similar to that in wild type infected mice.
These data strongly suggest that WNV infection within the CNS
triggers a CCR5-dependent inﬂux of leukocytes into the CNS that
is required for viral clearance and survival (Figure 2).
Similar results, showing a critical role for CCR5 in host defense,
have been obtained in a mouse model of JEV infection (Larena
et al., 2012). Larena et al. reported that Ccr5−/− mice infected
with JEV exhibit increased mortality (64%) compared to wild type
mice (28%), correlatingwith higher viral titers in theCNS. Periph-
eral control of virus and the induction of the humoral immune
response were similar between wild type and Ccr5−/− mice. How-
ever, NK and CD8+ T-cell effector functions were blunted in the
absence of CCR5 compared to wild type mice (Figure 2). Rather
than a loss of leukocyte inﬁltration, as observed in WNV infec-
tion, a transient delay in the recruitment of NK cells, CD4+ and
CD8+ T-cells, and monocytes into the infected CNS was observed.
Together, these data suggest that the functions of CCR5 are crit-
ical for controlling both leukocyte trafﬁcking as well as effector
functions, which is required for efﬁcient clearance of virus from
the CNS.
During SFV infection in mice, evaluation of chemokine tran-
script numbers in the CNS revealed high induction of CCL3,
CCL4, and CCL5 expression, suggesting a possible role for
CCR5 in pathogenesis of SFV (Michlmayr et al., 2014). Although
Ccr5−/− mice have not been tested, we evaluated the efﬁcacy of
a small molecule CCR5 receptor antagonist, named DAPTA, in a
mouse model of SFV. DAPTA is a synthetic peptide comprising
eight amino acids (185–192) of the gp120 V2 region of HIV-
1 that binds competitively to the ligand-binding site of CCR5
(Polianova et al., 2005). Mice were infected with either the avir-
ulent or virulent strain of SFV and then treated subcutaneously
once daily with DAPTA, starting on day 3 post infection. The
results reveal no signiﬁcant difference in mortality during vir-
ulent SFV infection and no signiﬁcant reduction of leukocytes
entering the brain of treated mice compared to untreated mice
(both virulent and avirulent strains; Table 1). However, the
number of CCR5 expressing cells in the brains of treated mice
was signiﬁcantly reduced compared to untreated mice, con-
ﬁrming the efﬁcacy of DAPTA in blocking CCR5. Our data
suggest that other chemokine receptors may be involved in
attracting leukocytes into the virally infected brain during SFV
infection.
Epidemiological studies
Based on the evidence in mouse models suggesting a critical neu-
roprotective role for CCR5 during ﬂavivirus infections, several
epidemiologic studies have been conducted to evaluate the role
of CCR5 in humans, speciﬁcally testing for the complete loss-of-
functionmutationCCR532. This phenotype is commonly found
at 10% allele frequency in the US (Zimmerman et al., 1997; Berger
et al., 1999). In the context of WNV infection, several initial cohort
studies, using patient samples collected from the US epidemic,
showed a signiﬁcant increase in CCR532 homozygosity among
WNV infected individuals with symptomatic outcome compared
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 264 | 5
Michlmayr and Lim Chemokines during arboviral encephalitis
to uninfected controls (Glass et al., 2006; Lim et al., 2008, 2010).
Further, the frequency of the CCR532 mutation among WNV
infected individualswho remained asymptomaticwas signiﬁcantly
depressed compared to controls, suggesting that all WNV infected
CCR532 homozygotes progress to symptomatic disease (Lim
et al., 2010). Evaluation of CCR532 heterozygotes showed no
increased susceptibility, suggesting that partial functionality of
CCR5 was sufﬁcient to confer protection (Lim et al., 2010). How-
ever, these ﬁndings have recently been challengedby twoadditional
studies, which failed to ﬁnd any association of symptomatic WNV
infection and CCR532 mutation. Reasons for these discrepant
results may be due to differences in study design, cohort size,
and/or race composition of the tested cohorts and control pop-
ulations (Bigham et al., 2011; Loeb et al., 2011). Further studies,
using large and well characterized cohorts, in which symptom
development is documented, should be conducted.
The frequency of the CCR532 mutation has also been evalu-
ated in a cohort of TBEV-infected patients (Kindberg et al., 2008).
Genotyping for the CCR532 mutation revealed an increased fre-
quency among TBE patients, compared to the aseptic meningoen-
cephalitis and control group. Furthermore, the allele frequency
of CCR532 correlated with disease severity. Although this study
evaluated a small number of patients, these data suggest that the
CCR532 mutation may be a risk factor for developing severe
disease after TBEV infection. In a follow up study by Barkhash
et al. (2013) using a larger cohort, the authors found no signiﬁ-
cant association between CCR532 mutation and predisposition
to TBE.
Among the encephalitic ﬂaviviruses, JEV is responsible for
the most cases of encephalitis worldwide (Campbell et al., 2011).
Although CCR5 is a critical host factor during JEV infection
in mice, an evaluation of CCR532 in patients would be difﬁ-
cult in cohorts of JEV-infected individuals, since endemic areas
are expected to have a low or absent CCR532 allele fre-
quency (Zimmerman et al., 1997; Berger et al., 1999). However,
there are several other CCR5 polymorphisms described in the
literature that strongly modulate CCR5 expression, and geno-
type:phenotype association studies using these genetic probes are
feasible (Carrington et al., 1999).
CCR5 receptor antagonists
Studies in mice, along with epidemiologic data, suggest that
CCR5 is protective in WNV, JEV, and TBEV infection, which
highlights the concern for chronic use of CCR5 antagonists in
humans. Maraviroc is an FDA-approved CCR5 antagonist that is
currently approved for the treatment of HIV-infected patients.
Further, this antagonist is being considered for several other
inﬂammatory diseases, with anticipated long-term use (Velasco-
Velazquez et al., 2012; Wilkin and Gulick, 2012; Cipriani et al.,
2013; Ochoa-Callejero et al., 2013). Based on epidemiologic data
showing no change in susceptibility among CCR532 heterozy-
gotes, the risk of CCR5 blockade will depend on the amount
of CCR5 coverage achieved by the drug. We would anticipate
that cessation of CCR5 blockade should fully restore the func-
tionality of this chemokine receptor, in the event that a patient
prescribed CCR5 blockers develops symptoms associated with ﬂa-
vivirus infection. More studies will be required to fully understand
the impact of CCR5 antagonists during ﬂavivirus infection in
humans.
CXCR2
Neutrophils are an important cellular component of the innate
immune response and appear to have a role in the pathogenesis
of ﬂavivirus infection of the CNS. During WNV encephalitis in
mice, neutrophils comprise a signiﬁcant proportion of the cel-
lular inﬁltrate within the CNS (Lim et al., 2011). Likewise in
humans, neutrophils were predominant in the CSF of patients
with neuroinvasive disease (Rawal et al., 2006; Tyler et al., 2006).
Like monocytes, neutrophils reside in the bone marrow, and their
mobilization is regulated, in part by CXCR2, a chemokine recep-
tor highly expressed on mouse and human neutrophils (Eash
et al., 2010). In mice, CXCR2 binds CXCL1 and CXCL2, while
in humans, this receptor binds most potently to CXCL8 (Murphy,
1997). A study by Bai et al. (2010) demonstrated that neutrophils
play a dual role during WNV infection. Using a Gr-1 or Ly6G
neutralizing antibody, the authors showed that depletion of neu-
trophils prior to infection resulted in reduced viral loads and
enhanced survival compared to untreated mice. However, if neu-
trophils are depleted 1 or 2 days after infection, greater viremia and
mortality was observed. These data suggest that, depending on the
timing of depletion, neutrophils can be either beneﬁcial and con-
tribute to viral clearance or can be detrimental and increase viral
dissemination of WNV in mice. The authors also evaluated the
mortality rate between WNV-infected wild type and Cxcr2−/−
mice, which revealed a signiﬁcant increase in survival time in
the absence of CXCR2 (Bai et al., 2010). Viremia was decreased
on day 1 in Cxcr2−/− mice, compared to wild type mice; how-
ever, by day 3, viremia was higher in CXCR2 deﬁcient mice.
These data suggest that CXCR2 is involved in early migration
steps that affect viral dissemination but may contribute to viral
clearance during the later phases of infection. Unfortunately, the
migration of neutrophils into the CNS was not measured in the
absence of CXCR2, and more studies are required to understand
the chemokine receptors required for their entry into the CNS and
their function.
No mouse studies have addressed the role of neutrophils dur-
ing JEV infection. However, several lines of evidence suggest that
these cells are important in vivo. Firstly, JEV has been shown to
induce neutrophilia in mice infected intraperitoneally; this has
also been observed in human infections as well (Chaturvedi et al.,
1979; Johnson et al., 1986; Mathur et al., 1988, 1992; Chung et al.,
2007). Secondly, signiﬁcant induction of CXCL8 levels was con-
comitant with the presence of neutrophils in the CSF of patients
positive for JEV (Winter et al., 2004). Notably, signiﬁcantly higher
levels of CXCL8 were associated with patient mortality (Singh
et al., 2000). Studies determining the signals involved in neu-
trophilia versus monocytosis, and how these are differentially
regulated during JEV and WNV infection, could provide use-
ful insights into the different clinical presentations observed in
patients.
Murray Valley encephalitis virus (MVEV) is a mosquito-
transmitted neurotropic ﬂavivirus, endemic to parts of Australia
and Papua New Guinea. Using a mouse model of MVEV infec-
tion, one study showed that the leukocytic inﬁltrate in the CNS
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predominantly comprised neutrophils, which appeared to colo-
calize with neurons and was preceded by the induction of CXCL1
expression (Andrews et al., 1999). Depletion of neutrophils, using
a Gr-1 antibody, resulted in increased survival (55%) compared to
isotype control-treatedmice,where infectionwas uniformly lethal.
These data suggest that the production of iNOS in the CNS may be
the mechanism by which neutrophils are promoting pathogenesis
in this model. No further studies were conducted to understand
the temporal and organ-speciﬁc roles of neutrophils in promot-
ing viral replication or to determine which receptor is utilized for
tissue migration.
In the context of SFV infection, we showed that neutrophil-
associated chemokines CXCL1 and CXCL2 were not expressed in
the brain of mice infected with the avirulent strain. Consistent
with this, no neutrophils were observed in the CNS as assessed by
ﬂow cytometric analysis and immunohistochemistry (Michlmayr
et al., 2014). In contrast to this, CXCL2 transcripts were highly
upregulated in murine brains infected with the virulent strain
of SFV, exhibiting a >2000-fold increase in CXCL2 transcripts
compared to healthy control brains. Neutrophils were detected in
the CNS of virulent SFV-infected mice by histology, and the extent
of CXCL2 upregulation correlated with disease severity, as lethally
SFV-infected mice displayed higher CXCL2 induction in the CNS
compared to asymptomatic mice (Michlmayr et al., 2014). The
function of neutrophils in this model is unclear, and more studies
are needed to understand their role, if any, in SFV and other
neurotropic alphavirus infections.
CXCR2 receptor antagonists
Because of the dominant role of CXCL8 in the activation and
recruitment of neutrophils in humans, several antagonists for its
receptors CXCR1 and CXCR2 have been developed for a wide
range of diseases, including COPD, cystic ﬁbrosis, and pancre-
atic islet transplantation (Horuk, 2009; Bachelerie et al., 2013).
Reparixin, a non-competitive allosteric inhibitor of CXCR1 and
CXCR2, appears to be the farthest along, having now entered
clinical phase III trials in Europe and the United States (Citro
et al., 2012). Several others are also in the pipeline, including
ones speciﬁc for CXCR2 (Dwyer et al., 2006; Chapman et al., 2007;
Gonsiorek et al., 2007). The function of neutrophils during ﬂa-
vivirus infection, both in the periphery and CNS, is unclear.
However, since depletion of neutrophils prior to infection pro-
motes survival, individuals chronically administered CXCR1/2
antagonists may experience some level of protection during WNV
infection. In the rare event that an individual is administered a
CXCR1/2 blocker soon after infection, increased WNV replica-
tion in the periphery could result in a more aggressive disease
outcome.
CXCR3
The chemokine receptor CXCR3 is found at high levels on acti-
vated T-cells and NK-cells, and it can bind to chemokine ligands
CXCL9, CXCL10, or CXCL11. The induction of these ligands is
nearly always associated with cell-mediated immunity, and these
chemokines are considered to be interferon-stimulated genes.
The recruitment of antigen-speciﬁc T-cells is a critical step in
viral clearance within the CNS, and the CXCL10:CXCR3 axis
appears to be particularly important in this process, at least in
the context of WNV (Figure 3). CXCL10 is the most highly
induced chemokine in the CNS in mouse models of WNV, JEV,
TBEV, and SFV encephalitis (Klein et al., 2004; Glass et al., 2005;
Garcia-Tapia et al., 2007; Cao et al., 2011; Yang et al., 2011; Palus
et al., 2013; Michlmayr et al., 2014). In addition, the other CXCR3
ligands, CXCL9 and CXCL11, are also often upregulated in the
infected CNS, although no studies have evaluated the role of these
chemokines in vivo (Klein et al., 2004; Glass et al., 2005; Michlmayr
et al., 2014).
Themost thorough analyses of CXCL10 andCXCR3 come from
data collected forWNV infection. InWNV-infected blood donors,
CXCL10 is signiﬁcantly upregulated in the plasma during the
viremic phase of infection, with levels signiﬁcantly decreased after
seroconversion, consistent with its role as an interferon-stimulated
gene (Tobler et al., 2008). Although in vitro studies using primary
brain cell cultures, showed CXCL10 expression in WNV-infected
astrocytes and microglia, the production of CXCL10 in vivo
appears to be primarily by infected neurons (Cheeran et al., 2003;
Shirato et al., 2004; Klein et al., 2005). Using CXCL10-deﬁcient
mice andananti-CXCL10neutralizing antibody,Klein et al. (2005)
observed a signiﬁcant reduction in CD8+ T-cells within the CNS,
higher viral titers in the brain, and enhanced mortality compared
with wild type mice (Table 1). These results were phenocopied
using Cxcr3−/− mice (Zhang et al., 2008). Of note, the number of
CD4+ T-cells was not signiﬁcantly reduced in the WNV-infected
brain, suggesting thatCXCL10 is important for the speciﬁc recruit-
ment of CD8+ T-cells and that other receptors may compensate
for the recruitment of CD4+ T-cells (Figure 3). Additionally, the
effect of CXCL10 on the pathogenesis of WNV infection appears
to be CNS-speciﬁc since clearance of WNV in peripheral tis-
sues were identical compared to wild type infected mice (Klein
et al., 2005). Thus, these data show an indispensable role for
CXCL10 in the recruitment of CXCR3-expressing CD8+ T-cells
into the CNS.
In addition to the role of the CXCL10:CXCR3 axis in regulat-
ing CD8+ T cell migration into the CNS, a more recent study has
demonstrated a role for this chemokine:receptor pair in promoting
neuronal apoptosis during WNV encephalitis. The authors found
that TNF-α produced during WNV encephalitis caused speciﬁc
downregulation of CXCR3 expression on infected and bystander
neurons. Downregulation of CXCR3 through pretreatment with
TNF-α or in Cxcr3−/− mice resulted in increased neuronal sur-
vival through delayed activation of caspase 3. These data suggest
that although CXCL10:CXCR3 signaling is protective in its capac-
ity to promote effector CD8+ T-cell migration to assist with
viral clearance, the same signaling event on neurons may induce
neuronal apoptosis and exacerbate immune-mediated damage
(Figure 3). These data exemplify the complexity of chemokines
during CNS inﬂammation and suggest that the use of CXCR3-
speciﬁc antagonists may be beneﬁcial or detrimental, depending
on cell-type speciﬁc effects and timing.
In TBEV-infected patients presenting with neuroinvasive dis-
ease, two studies reported high levels of CXCL10 in the CSF
(Lepej et al., 2007; Zajkowska et al., 2011); cytoanalysis of CSF
samples revealed that the majority of CD4+ T-cells were posi-
tive for CXCR3. These data suggest that the CXCL10:CXCR3 axis
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FIGURE 3 |The role of CXCR3 and CXCR4 during arbovirus-induced
encephalitis in mice. (1a) CXCR3+CD8+ T-cells migrate into the CNS in
response to high levels of neuronal CXCL10. Loss of CXCR3 or its ligand
CXCL10, or antagonizing this interaction (1b) prevents the migration of
CD8+ T-cells into the CNS during WNV in mice. (2a) Virally infected
neurons are the predominant source of CXCL10 in the CNS during WNV
infection. (2b) Neuronal CXCL10 can engage CXCR3 that is upregulated on
infected neurons and induce apoptosis. (2c) Blockade of CXCR3 with
antagonists or CXCL10 neutralizing antibodies leads to the reduced binding
of neuronal CXCL10 to neuronal CXCR3 and result in reduction of apoptosis
and increased neuronal survival. (3a) During WNV infection, CXCR4+CD8+
T-cells migrate toward endothelial CXCL12, expressed on the inﬂamed
cerebral endothelium. (3b) The interaction of CXCL12 and CXCR4 causes
the CD8+ T-cells to be retained within the perivascular space. (3c,d) After
blockade with the CXCR4 antagonist, AMD3100, the CD8+ T-cells are
released and can migrate into the brain parenchyma where they promote
clearance of WNV. Pathological steps are depicted in red; beneﬁcial steps
involved in increasing survival and improving disease outcome in the host
are depicted in green. Gray arrows signify functions that are neither
beneﬁcial nor pathogenic.
may also be critical for T-cell migration into the CNS. Although
CXCL10 expression is highly upregulated in theCNS during TBEV
infection in mice, the speciﬁc role of these cells in directing T-cell
migration into the CNS has not been studied (Tigabu et al., 2010;
Palus et al., 2013).
In the context of alphavirus infection, the role of CXCR3hasnot
been evaluated yet. CXCL9 and CXCL10 are highly upregulated in
the CNS of SINV-infected mice, and preceded the inﬁltration of
T-cells and B-cells (Metcalf et al., 2013). Flow cytometric analyses
of B-cells within the SINV infected CNS revealed high and uni-
form expression of CXCR3 on these cells. During SFV infection
with both virulent and avirulent strains, CXCL9 andCXCL10were
highly upregulated in the CNS of infected mice as well, correlating
with a large inﬂux of T-cells, primarily CD8+ T-cells, into the CNS
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(Michlmayr et al., 2014). To evaluate the role of CXCR3 in the con-
text of SFV infection, we employed a small molecule antagonist,
compound 21, an imidazo-pyrazine derivative, which has been
shown to block binding of CXCL9, CXCL10, and CXCL11, and
is speciﬁc for CXCR3 (Du et al., 2009). SFV-infected mice were
treated subcutaneously once daily starting on day 3 post infection.
Treatment of avirulently infectedmice with compound 21 resulted
in a signiﬁcant decrease of T-cell inﬁltration into the CNS com-
pared to untreated mice, suggesting that CXCR3 is involved in the
T-cell migration into the inﬂamed brain (Figure 3). Surprisingly,
blockade of CXCR3 during lethal SFV infection did not result in
a change in survival (Table 1). However, the combined blockade
of CXCR3 and CCR2, did result in signiﬁcantly enhanced survival
compared to untreated mice (Table 1). Thus, the dual blockade of
CXCR3 and CCR2 is necessary to achieve a survival beneﬁt during
lethal SFV-induced encephalitis. It is likely that these antagonists
are inhibiting both T-cells and monocytes, implying that lethal-
ity in this model is immune-mediated. Furthermore, our data
suggest that dual blockade of chemokine receptors may be more
effective for treating diseases, a paradigm known as polypharma-
cology (Roth et al., 2004; Frantz, 2005; Overington et al., 2006).
This concept is reviewed in more detail elsewhere (Overington
et al., 2006; Horuk, 2009).
CXCR3 receptor antagonists
Compound 21, synthesized by Amgen, has been shown to bind
to CXCR3 with high potency, inhibiting the binding of cognate
CXCR3 ligands (Du et al., 2009). In addition to this compound,
there are several other CXCR3 blockers in clinical development for
the treatment of rheumatoid arthritis and psoriasis and is exten-
sively reviewed elsewhere (Bachelerie et al., 2013; Michlmayr and
McKimmie, 2014). At least during WNV infection, there appears
to be a dual function of the CXCR3:CXCL10 axis; ﬁrstly, for the
recruitment of antiviral CD8+ T-cells into the CNS, and secondly,
to promote neuronal apoptosis (Klein et al., 2005; Bhowmick et al.,
2007; Zhang et al., 2008). Despite this, the effect of global CXCR3
and CXCL10 deﬁciency resulted in increased mortality, suggesting
that the dominant protective function of CXCR3 is at the level of
CD8+ T-cell migration into the CNS,which strongly outweighs its
role in promoting neuronal apoptosis (Zhang et al., 2008, 2010).
Thus, we anticipate that the blockade of CXCR3 during ﬂavivirus
induced encephalitis may promote pathogenesis. In addition to
CXCR3 antagonists, a neutralizing CXCL10 antibody, MDX-1100,
is also being tested by Medarex for the treatment of rheuma-
toid arthritis and is currently in clinical phase II studies (Yellin
et al., 2012). Similar to CXCR3 antagonism,MDX-1100 may block
effector T-cell migration into the CNS and increase pathogenesis.
CXCR4
CXCR4 and its sole ligand CXCL12 are among the most
highly conserved in the chemokine superfamily (Lee et al.,
1999; Zlotnik et al., 2006). CXCR4 has multiple critical functions,
including embryonic development, homeostasis, and lymphoid
organ retention as well as in serving as a coreceptor for HIV-1.
As a result of its role in HIV entry, a small molecule inhibitor,
AMD3100, was identiﬁed as a potent and selective antagonist for
CXCR4. Under the name Plerixafor or Mozobil, AMD3100 is now
FDA-approved and used to mobilize stem cells in non-Hodgkin
lymphoma and multiple myeloma patients.
The role of CXCL12:CXCR4 during CNS inﬂammation in ﬂa-
vivirus and alphavirus infections is not well characterized. Because
of the known role of the CXCL12:CXCR4 axis in cellular retention
within the bone marrow, McCandless et al. (2008) hypothesized
that the interaction of CXCL12 could be an important retention
signal for cells migrating into the CNS. Indeed, CD8+ T-cells
are restricted at the BBB through interactions with endothelial
CXCL12 (Figure 3). Interrupting this interaction through the
continuous administration of AMD3100 from the initial time
of WNV infection in mice, resulted in the release of CD8+ T-
cells in the perivascular space, allowing subsequent migration of
these cells into the brain parenchyma, and is leading to enhanced
viral clearance and survival (Figure 3; Table 1). Importantly,
the authors showed the same pattern of perivascular retention
of T-cells through CXCL12 and CXCR4 expression patterns in
WNV-infected patients with neuroinvasive disease (McCandless
et al., 2008). The authors also showed that glial cell activation was
decreased in AMD3100-treated mice that can subsequently mini-
mize pathological immune activation within the CNS. These data
are even more impressive and relevant, since AMD3100 would
be expected to function similarly in infected humans due to high
conservation of CXCR4 between mice and humans.
CXCR4 receptor antagonists
Since AMD3100 is already FDA-approved (Mozobil, Plerixafor),
the use of this antagonist for the treatment of WNV-infected indi-
viduals is possible. In fact, McCandless et al. (2008) have demon-
strated that treatment of WNV-infected mice with AMD3100,
starting on day 4 post infection, led to a prolonged survival,
although no overall survival beneﬁt was observed. These data are
still very encouraging since increasing survival time, along with
supportive care or in combination with other therapeutics as they
become available, may provide important therapeutic options. In
mice and humans,AMD3100 is capable of increasing overall num-
bers of leukocytes in the blood, which may also contribute to
enhanced survival (Capoccia et al., 2006; McDermott et al., 2011).
CONCLUSION
The emergence and spread of arboviral infections in the past
few decades has highlighted the unpredictable nature of human
outbreaks and emphasizes the need for novel treatment and pre-
vention measures. The recent outbreak of WNV disease in the
United States, and its continued emergence in several regions
within Europe are just a few examples (Centers forDisease Control
and Prevention [CDC], 2013; Sambri et al., 2013). Although there
are vaccines available for the prevention of JEV and TBEV infec-
tion, no vaccines exist for human WNV infection, and no speciﬁc
therapeutics are currently available for the treatment of neuroinva-
sive diseases caused by any arbovirus. Therefore, there is an urgent
need for novel intervention strategies, either in the form of antivi-
rals or immunomodulators that can block viral replication, boost
protective immune responses, and minimize CNS injury. Further-
more, these therapeutics should be efﬁcacious after the onset of
symptoms, when the virus has entered the CNS and neuroinvasive
symptoms have developed in patients.
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Leukocyte migration is critically important during all phases
of viral replication in vivo, and it is apparent that the chemokine
network plays an integral role in the generation of an effec-
tive host immune response in the CNS. It is clear that both
innate and adaptive immune responses are required for respond-
ing to and counteracting viral replication and spread, and since
naturally acquired arboviral infections are initiated in the periph-
ery, the timing and magnitude of both innate, as well as T-
and B-cell responses, are critical for efﬁcient viral control once
the virus has accessed the CNS (Samuel and Diamond, 2005;
Diamond and Gale, 2012). However, viral infections within the
CNS require a response that is rapid and effective, but is not
excessively exuberant as this could cause collateral damage to
functionally critical and non-renewable cell types. A suboptimal
or excessive immune response, or insufﬁcient timing of immune
responses, could alter the outcome of arboviral infections. Stud-
ies investigating chemokine-mediated leukocyte trafﬁcking as well
as other non-trafﬁcking related functions during arboviral infec-
tions have provided great insight into our understanding of viral
pathogenesis. Despite the great redundancy in the system, critical
and non-overlapping functions for speciﬁc chemokines and recep-
tors have been identiﬁed. Indeed, the migration of cells from the
blood into the CNS, activation of effector cell function, mobiliza-
tion of leukocytes, and retention of cells in the perivascular space
are just a few examples. Thus, manipulating chemokine recep-
tors therapeutically is a particularly attractive means by which
to modulate outcome of infection. However, it is important to
note that nearly all of the data so far have been evaluated using
knock-out systems in mice; thus, our knowledge of the role of
chemokine receptors on speciﬁc subsets of cells is incomplete pri-
marily due to the lack of conditional knock out systems for most
chemokine receptors. As reagents become available, it is imperative
to further our understanding of how each receptor functions in
a cell-type and organ-speciﬁc manner. Furthermore, chemokine
receptor antagonistsmay bemore relevant to understand the effect
of therapeutics on disease outcome compared to knock-out model
systems.
There are many areas of research that have remained relatively
unexplored with regards to arboviral encephalitides: What are the
key chemokine-mediated events that take place in local draining
lymph node? What receptors coordinate optimal B- and T-cell
activation within lymphoid tissues? How do neutrophils mobi-
lize and migrate into the CNS? Still many questions remain, and
there are many cell types that have not been studied in the context
of arboviral encephalitis, most notably microglia. Several studies
have shown thatmicroglia are highly activated and proliferate dur-
ing WNV encephalitis, and studies in vitro have found that these
cells respond to virus through the TLR-3 pathway (Glass et al.,
2005; Town et al., 2006; Getts et al., 2008). However, the func-
tion of microglia during WNV encephalitis in vivo is currently
unknown. Since these cells exclusively express CX3CR1 in the
healthy CNS, and its ligand CX3CL1 is constitutively expressed
by neurons, this receptor:ligand interaction is likely to function
during infection (Harrison et al., 1998; Cardona et al., 2006; Com-
badiere et al., 2007). In a healthy brain, the interaction between
CX3CL1:CX3CR1 is hypothesized to suppress certain aspects of
microglial activity (Zujovic et al., 2000; Cardona et al., 2006).
Based on studies in numerous other models, loss of the signal,
as in the case of CX3CR1-deﬁciency, results in microglia display-
ing an increased propensity for activation and function (Liu et al.,
1998; Soriano et al., 2002; Sunnemark et al., 2005; Cardona et al.,
2006; Fuhrmann et al., 2010). How the loss of CX3CR1 expres-
sion on microglia alters the outcome of WNV and other arboviral
infections of the CNS will provide critical insights into their role
in neuropathogenesis.
The use of chemokine receptor antagonists is an active area for
drug development but is complicated by their pleiotropic func-
tions that may have opposing effects. One such example is the
dual role of CXCR3 during WNV pathogenesis. It has been shown
that CXCR3 is critical for CD8+ T-cell migration into the CNS
and promotes viral clearance and survival. However, it has also
been shown that neuronally expressed CXCR3, and its interac-
tion with CXCL10 on WNV-infected neurons, promotes neuronal
apoptosis. Thus, CXCR3 antagonism would have both a pro-
tective and pathogenic effect on disease outcome; the diametric
consequences of CXCR3 blockade could result in unanticipated
effects. Additionally, due to the positive and negative pressures
that contribute to the evolution of chemokine receptors over
time, the role of any given receptor could be beneﬁcial in one
setting and detrimental in another. This complexity is best illus-
trated with CCR5, which functions in promoting infection in
the context of HIV-1 infection but has the reciprocal effect dur-
ing WNV infection (Lim et al., 2006). Thus, CCR5 antagonism,
using FDA-approved Maraviroc for the treatment of HIV-infected
individuals, carries the cost of promoting symptomatic WNV
disease.
It is pivotal to understand the underlying immunological
mechanism of encephalitis in order to develop effective treat-
ment of acute viral encephalitis. New insights into the role of
chemokines and their receptors in these contexts are also informa-
tive for studies of brain inﬂammation caused by multiple sclerosis,
Alzheimer’s or Parkinson’s disease. The successful development
of CCR5 and CXCR4 antagonists in humans demonstrates that
chemokine receptors are feasible and effective targets that have
the capacity to modulate disease. In fact, studies in mice and
humans predict that these two antagonists would have oppo-
site effects in human WNV disease, with Maraviroc promoting
symptomatic disease and CXCR4 blockers promoting survival
during infection. Because most chemokine receptor antagonists
currently being developed will likely be administered chroni-
cally, it is critical to understand how these therapies may affect
the individual in the context of their speciﬁc infection. This
is an important goal that has been and should continue to be
tested in the laboratory setting. Moreover, it is important to
note that data obtained in inbred mouse models may not be
applicable to humans. Thus, treatment of infected individu-
als with chemokine receptor antagonists may not function as
anticipated based on mouse studies and should be approached
with caution. Despite the success of Maraviroc and Mozo-
bil/Plerixafor, there have been many receptor antagonists that
have failed in clinical trials. Due to the redundancy of the
chemokine system, antagonists that inhibit more than one recep-
tor or the use of several compounds in conjunction may prove
beneﬁcial.
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